Evidence map›Paper›PMID 39105778›Full record

ArticleJournal of medicinal chemistry2024

Development of VU6036864: A Triazolopyridine-Based High-Quality Antagonist Tool Compound of the M

Jinming Li, Douglas L Orsi, Julie L Engers, Madeline F Long, Rory A Capstick, Mallory A Maurer, Christopher C Presley, Paige N Vinson, Alice L Rodriguez, Allie Han and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Discovery of VU6052254: A Novel, Potent MACS chemical neuroscience · 2025
    Article
  2. Application of Deuterium in an MACS chemical neuroscience · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jinming LiWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Douglas L OrsiWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0001-6731-5494
Julie L EngersWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Madeline F LongWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0002-8933-3439
Rory A CapstickWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Mallory A MaurerWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Christopher C PresleyWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Paige N VinsonWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Alice L RodriguezWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0002-5244-5103
Allie HanWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Hyekyung P ChoWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Sichen ChangWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Megan JacksonWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Michael BubserWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Anna L BlobaumWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Olivier BoutaudWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Michael A NaderCenter for the Neurobiology of Addiction Treatment, Wake Forest School of Medicine, Medical Center Boulevard Winston-Salem, Winston-Salem, North Carolina 27157, United States.
Colleen M NiswenderWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
P Jeffrey ConnWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Carrie K JonesWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Craig W LindsleyWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0003-0168-1445
Changho HanWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID 0000-0002-0832-7070

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While the muscarinic acetylcholine receptor mAChR subtype 5 (M

Indexed as

PyridinesReceptor, Muscarinic M5AnimalsBrainCHO CellsCricetulusHumansMuscarinic AntagonistsRatsStructure-Activity RelationshipTriazolesMuscarinic AntagonistsPyridinesReceptor, Muscarinic M5Triazoles

Identifiers

PMID39105778
PMCPMC11345818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.